

THE RECALCITRANT CANCER RESEARCH ACT

AN IMPORTANT STEP TOWARD IMPROVING PANCREATIC CANCER SURVIVAL



Thanks to broad bipartisan and bicameral support, the Recalcitrant Cancer Research Act was signed into law on January 2, 2013, as part of the National Defense Authorization Act. The bill was originally introduced as the Pancreatic Cancer Research & Education Act by Representatives Anna Eshoo (D-CA) and Leonard Lance (R-NJ) and Senator Sheldon Whitehouse (D-RI) and was co-sponsored by 59 senators and 295 representatives at the time of passage.

The Act calls on the National Cancer Institute (NCI) to develop scientific frameworks, similar to strategic plans, for pancreatic and lung cancers and provides the NCI director with the authority to develop frameworks for other deadly cancers. These scientific frameworks will help provide the strategic direction and guidance needed to make true progress against recalcitrant, or deadliest cancers, which are defined by the statute as those with a five-year relative survival rate below 50 percent. Under the statute, the NCI was required to release scientific frameworks for pancreatic and lung cancers by July 2014. We applaud the NCI for releasing the "Scientific Framework for Pancreatic Ductal Adenocarcinoma" in February 2014, ahead of the statutory deadline. In July 2014, the NCI released the required scientific framework for small-cell lung cancer.

THE SCIENTIFIC FRAMEWORKS PROVIDE CRITICAL STRATEGIC DIRECTION FOR RESEARCH ON OUR NATION'S DEADLIEST CANCERS

Until the Recalcitrant Cancer Research Act was passed, there was no national strategic plan for addressing our nation's deadliest cancers. However, when fully implemented, the statute will provide that much-needed strategic guidance. Under the statute:

- Each scientific framework is required to include a review of the literature and promising advances, examine the number of researchers investigating the cancer, identify opportunities for coordinating NCI-funded research with research at other private and public entities, and identify public and private resources that can facilitate research into each particular recalcitrant cancer.
- The scientific frameworks are required to identify questions relating to basic, translational and clinical research that still need to be answered, to make "recommendations for appropriate actions" to address these questions, and to advance research in the prevention, diagnosis and treatment of each cancer. The statute also requires that the frameworks include "appropriate benchmarks to measure progress on achieving such actions," including ensuring adequate availability of researchers, promoting and developing initiatives and partnerships, and developing additional public and private resources.
- The steps taken to carry out the scientific frameworks are to be identified in the National Institutes of Health's (NIH) biennial report to Congress, including research grants awarded by the NIH, progress made in improving patient outcomes, such as relative survival rates, and updates on activities. The NIH's 2016 biennial report included a report on activities from FY2012-2013. Their 2018 report will show what progress has been made on the frameworks.
- The pancreatic and lung cancer frameworks are to be reviewed and updated by 2019. By July 2020, the NCI director must submit a report to Congress on the effectiveness of the frameworks on pancreatic and lung cancers in improving the prevention, detection, diagnosis and treatment of these cancers.
- The statute also requires the NCI director to consider the frameworks' recommendations when making decisions about exception funding.

WITH THIS ACT, CONGRESS HAS PROVIDED HOPE

The original underlying bill had overwhelming bipartisan support, acknowledging the need for a greater research focus on pancreatic cancer and other deadly cancers.

- Pancreatic cancer is one of the deadliest cancers. Of the major cancers, pancreatic cancer has the lowest five-year relative survival rate, currently 8 percent.^{1,2}
- Pancreatic ductal adenocarcinoma, the subject of the scientific framework released in February 2014, accounts for 95 percent of pancreatic cancer cases.¹
- In 2016, pancreatic cancer surpassed breast cancer as the third-leading cause of cancer death in the U.S. Also, deaths from liver cancer now exceed prostate cancer deaths, positioning liver cancer as the fifth leading cause of cancer-related death in the U.S. in 2016.¹
- A report published in *Cancer Research* in 2014 predicts the shifts mentioned above, and the authors further project that pancreatic cancer will surpass colorectal cancer to become the second leading cause of cancer-related death around 2020.³
- The same report predicts that by 2030, the top five cancer killers in the U.S. will be lung, pancreatic, liver, colorectal and breast – a significant shift from the ranking of lung, colorectal, breast, pancreatic and prostate at the time of publication.³ Lung, pancreatic and liver cancers are all considered to be deadly, or recalcitrant, cancers under the Recalcitrant Cancer Research Act. Their expected rise in the rankings of cancer killers underscores the need for a greater federal research investment to prevent these predictions from coming true.
- The other site-specific cancers that are considered recalcitrant, according to the statutory definition, include brain, esophageal, ovarian and stomach cancers, as well as myeloma.

THE STATUTE HAS CREATED A PATH FOR PROGRESS IN PANCREATIC CANCER RESEARCH

The scientific framework for pancreatic cancer was built upon a report that the NCI released in June 2013 called “Pancreatic Cancer: Scanning the Horizon for Focused Interventions.” The Horizon Scan report proposed four specific initiatives for advancing pancreatic cancer research. The framework expands on these recommendations by providing specific suggestions for moving forward for each one. The NCI has made important progress on the four key recommendations detailed below and has taken specific steps toward implementing them.

UNDERSTANDING THE BIOLOGICAL RELATIONSHIP BETWEEN PANCREATIC CANCER AND DIABETES

The NCI and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with added support from the Pancreatic Cancer Action Network, sponsored a meeting in June 2013 that gave rise to a request for grant applications (RFA) to create a new research consortium. The NCI and NIDDK created the Consortium to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) and in September 2015, 10 clinical centers were selected and approved for funding. The CPDPC is meeting regularly, and one of their major projects is the development of a cohort of new-onset diabetics for the purpose of validating assays for the early detection of pancreatic cancer.

EVALUATING SCREENING PROTOCOLS FOR BIOMARKERS FOR EARLY DETECTION

In June 2015, the NCI issued a Program Announcement inviting multidisciplinary teams to submit proposals aimed at establishing the Pancreatic Cancer Detection Consortium to improve early detection and characterization of precursor lesions. Applications are due between November 2015 and April 2018, and the first round of recipients have been announced. The NCI is organizing a meeting for December 2016 to coordinate efforts between several NIH programs designed to identify biomarkers for the early detection of pancreatic cancer.

WHAT WE ARE ASKING FROM CONGRESS

The Recalcitrant Cancer Research Act and the NCI’s scientific framework on pancreatic ductal adenocarcinoma are important milestones toward improving survival rates. As the NCI continues to work on the implementation of each initiative, we look forward to collaborating on next steps and updating Congress on progress. This has been a positive step forward for pancreatic cancer, and we hope that the NCI will continue to create frameworks for additional deadly cancers.

While we are grateful to Congress for the historic NIH and NCI funding increases in FY2016, we are deeply concerned that the NIH budget is still nearly 18 percent below its FY2003 level, when accounting for inflation. Ten years ago, the NIH funded nearly one out of three grant applications; now, that number has dropped to about one in seven. Funding for the NCI has declined even more.

We applaud President Obama’s call for a Cancer Moonshot as it offers a unique opportunity to make progress against pancreatic cancer and others that are defined by the Recalcitrant Cancer Research Act as our nation’s deadliest cancers. The fact that pancreatic cancer has surpassed breast cancer to become the third leading cause of cancer-related death and is expected to become second by 2020 only underscores the urgency of ensuring that the down payment Congress made on NIH and NCI funding is continued.

We cannot hope to have success in diseases like pancreatic cancer without putting the NIH and NCI on a path for robust sustained growth. Furthermore, it will be difficult to leverage the opportunities that come out of the scientific framework developed as a result of the Recalcitrant Cancer Research Act without continuing the progress Congress started last year toward restoring NIH funding. We therefore urge Congress to fully fund the Cancer Moonshot so that we can capitalize on promising new initiatives and increase momentum in ongoing pancreatic cancer research.

THE PANCREATIC CANCER ACTION NETWORK CALLS ON THE 114TH CONGRESS AND THE ADMINISTRATION TO WAGE HOPE BY:

- Putting the NIH on a path of sustained growth by passing a final FY2017 budget package before the end of the calendar year that provides a minimum of a \$2 billion increase for the NIH and includes funding for the Cancer Moonshot to accelerate progress against this deadly disease.
- Allocating a portion of the Cancer Moonshot funds to research on our nation’s deadliest cancers – the recalcitrant cancers that have five-year survival rates below 50 percent.
- Continuing to include pancreatic cancer in the Department of Defense Peer Reviewed Cancer Research Program and providing \$60 million, as recommended by the Senate Appropriations Committee.
- Completing work on a 21st Century Cures/Innovations for Healthier Americans Initiative legislative package that includes mandatory funding that supplements, not supplants, NIH annual appropriations.
- Joining the bicameral Congressional Caucus on the Deadliest Cancers.

Sources for statistics:

1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016.
2. “Major cancer” is defined as one tracked by both the American Cancer Society and the National Cancer Institute.
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. *Cancer Res.* 2014; 74(11):2913-2921.

©2016 Pancreatic Cancer Action Network. All rights reserved. GAA102 NOV 2016

STUDYING NEW STRATEGIES IN IMMUNOTHERAPY

An NCI task force identified that understanding the interaction between cancer cells and immune cells in the tumor microenvironment is essential to developing new immunotherapies for pancreatic cancer. In 2016, the NCI provided funding to nine institutions to make progress in this area. The NCI is now preparing to release a Request for Applications to support a consortium of up to five institutions to work collaboratively to advance this field and conduct early clinical trials to identify new immunotherapies for the treatment of pancreatic cancer.

DEVELOPING NEW TREATMENT APPROACHES THAT INTERFERE WITH RAS ONCOGENE-DEPENDENT SIGNALING PATHWAYS

In 2013, the NCI launched the RAS Initiative with significant funding attached. The project has the potential to increase the survival rate for pancreatic cancer as well as for other forms of cancer that are driven by RAS. Now that the implementation plan has launched, the NCI is working on developing methods of assessing the progress of this initiative.

National Office
1500 Rosecrans Ave., Ste. 200
Manhattan Beach, CA 90266
Government Affairs & Advocacy Office
1050 Connecticut Ave. NW, Ste. 500
Washington, DC 20036

PANCREATIC
CANCER
ACTION
NETWORK